Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Stock Report

| More

Bal Pharma poised to strengthen its position in diabetes segment through its API Gliclazide

Posted On: 2021-09-28 14:36:17 (Time Zone: IST)

Bal Pharma, a fully integrated pharmaceutical Company specialized in Prescription Drugs, Generics, pharma intermediates and Bulk Actives is further strengthening its market leading position in Active Pharmaceutical ingredient (API) Gliclazide with higher capacity utilization at the existing facility, and the streamlining of new facility that commenced production of Gliclazide in September, 2020.

Bal Pharma is one of the largest producers and exporters of an API Gliclazide, which is used to treat type 2 diabetes. The company has a total capacity to manufacture 17.5 MT Gliclazide per month. One of the manufacturing facilities located at Bommasandra, Bangalore, with the capacity of 7.5 MT per month, its capacity utilization dip to 60% due to Covid related lockdown, which bounced back to 85% utilization level in FY2021. The second unit with a manufacturing capacity of Glicalzide of 10 MT per month is located at Udaipur , Rajasthan which has started production in September , 2020. This new facility operated at 35% utilization during FY2021 which has now stabilized and has been operating at 45% during the first five months of FY2022. With improved utilization, Bal Pharma is further strengthening its market leading position in Gliclazide. The Company expects to achieve an average utilization of 70% of its Gliclazide capacity in FY2022.

Gliclazide, API is a sulfonyl urea component used for treating type 2 Diabetes, has been an important contributor in the company's earnings. In terms of volume, Bal Pharma controls over 25% of the world's Gliclazide market of 415 tonnes as per IQVIA report and is growing at the rate of 5% per annum. Company also captively consumes its Gliclazide for manufacturing formulations. Its Domestic formulations are sold under the brand name DIABEND. The Company generated about 44 % of its total revenues from Gliclazide in FY2021. Company generated %100 crores of revenue in FY21 from Gliclazide (API+ Formulations) Although, the company has increased focus on marketing the other products aggressively, Bal Pharma's API revenues are likely to be substantially contributed by gliclazide in the medium term given the time lag expected in ramp up of new products.

Bal Pharma Gliclazide API exports footprint covers more than 35 countries across the world. The Company is targeting to further expand geographic presence in Gliclazide and has supplied samples to new customers. Domestic market for Gliclazide (API + Formulations) is close to 60% of overall sales of Gliclazide for FY21.

Besides improving the market share, Bal Pharma is also committed to reduce import dependency for Gliclazide raw material N-Aminio Azabicyclo octane (3,3,0) hydrochloride. Around 70-75% of the raw material for this product is imported from China. To reduce the exposure and dependence of import, the Company has tied up with domestic suppliers for sourcing raw materials and is also exploring opportunities for backward integration. The Company is confident of reducing the imports to less than 33% over the next three years. Overall. import as a per centage of total raw materials for FY2020 and FY2021 stood at 34% and 42% respectively.

"Bal Pharma has managed to improve its capacity utilization following the easing of Covid related supply chain and logistical issues. With this, the Company is poised to further strengthen its market leading position in diabetes as a therapeutic segment. Bal Pharma's leading product Gliclazide enjoys consistently growing demand from customers across continents, enjoying sizable brand equity in API and formulations. Soon the Company will launch its formulation of Gliclazide MR 30 and 60 mg tablets in the EU market and is expected to file dossier in Q1FY23. While Africa and Latin America remains the dominant market for export formulations, the Company is targeting increasing its presence in various other geographies like Southeast Asia and CIS countries." said Mr. Shailesh Siroya, Managing Director, BAL Pharma.

Shares of Bal Pharma Ltd. was last trading in BSE at Rs. 102.15 as compared to the previous close of Rs. 104.45. The total number of shares traded during the day was 11095 in over 484 trades.

The stock hit an intraday high of Rs. 105.6 and intraday low of 101.5. The net turnover during the day was Rs. 1145865.

Click here to send ur comments or to

Other Headlines:

Rattanindia backed Revolt opens EV dealership in Jaipur

SecureKloud Technologies Limited allots 2,84,000 shares on conversion of warrants

IEX to commence trade in Energy Saving Certificates under PAT Cycle- II on 26 October 2021

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination

Godrej Properties in partnership with Dasra Launches report

EOS Data Analytics Partners up with Cambridge Technology in the agriculture and forestry sectors

Balu Forge Industries Ltd Board to consider Interim Dividend for FY22

Karda Constructions Ltd announces Q2FY22 results

ICRA Ltd reports consolidated PAT of Rs. 24.05 crore in Q2FY22

IndiGo partners Kotak Mahindra Bank for Ka-ching co-branded credit card

Apollo Hospitals announces free COVID vaccinations for children with Co-Morbidities

Bharat Petroleum to strengthen rural market connect with launch of new campaign by MAK Lubricants

ANG Lifesciences India Ltd board declares interim dividend of Rs. 1

Home First Finance Company India Limited - Highlights for Q2FY22

Advitiya Trade India Ltd to consider migration to main board of BSE

Quick Heal Technologies Ltd Q2FY22 consolidated PAT at Rs. 34.62 crore

ANG Life Sciences India Ltd H1FY22 consolidated PAT zooms to Rs. 33.77 crore

Jagran Prakashan Ltd posts consolidated net profit of Rs. 61.83 crore in Q2FY22

Choksi Imaging Ltd posts Rs. 46.46 lakhs net profit in Q2FY22

CEAT Ltd consolidated Q2FY22 net profit climbs QoQ to Rs. 41.98 crore

Sheetal Diamonds Ltd Q2FY22 loss at Rs. 40.44 lakhs

Orbit Exports Ltd Q2FY22 consolidated net profit higher at Rs. 4.54 crore

Indus Towers Ltd reports Rs. 1558.5 crore consolidated profit in Q2FY22

Sagar Productions Ltd posts Rs. 11.26 lakhs PAT in Q2 FY2021-22

Orient Cement Ltd reports Rs. 56.88 crore profit in Q2 FY22

Shreenath Investment Company Ltd Q2FY22 PAT slides to Rs. 5.61 lakhs

Home First Finance Company India Ltd posts Rs. 44.86 crore PAT in Q2 FY2021-22

Hardcastle and Waud Mfg Co. Ltd. Q2FY22 profit jumps to Rs. 69.41 lakhs

LKP Securities Ltd Q2FY22 consolidated net profit at Rs. 3.80 crore

Mangalam Organics Limited to double Camphor production capacity to 10,000 MTPA

Dwarikesh Sugar Industries Ltd - Q2FY22 Highlights

Kansai Nerolac Paints Ltd board declares interim dividend of Rs. 1.25

Mangalam Organics Ltd Q2FY22 consolidated PAT jumps to Rs. 22.31 crore

Mahan Industries Ltd posts loss in Q2FY22

Vardhman Special Steels Ltd Q2FY22 PAT drops QoQ to Rs. 24.29 crore

HDFC Asset Management Company Ltd posts Q2FY22 net profit of Rs. 344.38 crores

Tech Mahindra Ltd board declares special dividend of Rs. 15

TCS Named a Leader in IDC MarketScape for Worldwide Artificial Intelligence IT Services

SunEdison Infrastructure Ltd forms subsidiary

Rama Steel Tubes Limited wins Business Excellence Award of the Year

Maharashtra Scooters Ltd Q2FY22 PAT zooms to Rs. 135.70 crores

Tech Mahindra Ltd consolidated Q2FY22 net profit slips QoQ to Rs. 1338.7 crore

Bigbloc Construction Ltd Q2FY22 consolidated PAT at Rs. 3.14 crore

Kansai Nerolac Paints Ltd reports consolidated PAT of Rs. 92.01 crore, down QoQ, YoY

Shriram Asset Management Company Ltd Q2FY22 net profit at Rs. 19.54 lakhs

The Ugar Sugar Works Ltd starts sugar crushing for 2021-22 season

Aurionpro Solutions Ltd Q2FY22 consolidated PAT up at Rs. 19.57 crore

Dwarikesh Sugar Industries Ltd Q2 FY2021-22 net profit rises to Rs. 39.62 crore

Som Datt Finance Corporation Limited Q2FY22 net profit drops QoQ to Rs. 1.75 crore

GMDC posts consolidated PAT of Rs. 40.45 crore in Q2FY22

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020